Junichi Azuma

Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production

Chian Ju Jong, Junichi Azuma, Stephen Schaffer · Amino Acids · 2011 · 466 citations

Life Sciences, Biochemistry, Cell Biology +14

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

Naoki Nishimoto, N. Miyasaka, Kazuhiko Yamamoto et al. · Annals of the Rheumatic Diseases · 2008 · 337 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Junichi Azuma, Masako Ohno, Ryuji Kubota et al. · European Journal of Clinical Pharmacology · 2012 · 273 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Masako Ohno, Ichiro Yamaguchi, Itiro Yamamoto et al. · PubMed · 2000 · 255 citations

Veterinary Medicine, Genetics, Pharmacology +15

Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations

S P Myrand, Kanako Sekiguchi, MZ Man et al. · Clinical Pharmacology & Therapeutics · 2008 · 225 citations

Medicine, Pharmacokinetics, Pharmacology +17